A Phase 3 clinical trial evaluating CagriSema (Cagrilintide B and Semaglutide I) for people with excess body weight reached primary completion on April 22, 2026. The study, which enrolled 300 participants, aimed to assess how well different doses of the combination medicine help with weight loss.
Background
CagriSema is an investigational medicine developed by Novo Nordisk, combining cagrilintide and semaglutide. It is being studied for its potential to help individuals with excess body weight lose weight. Currently, CagriSema cannot be prescribed by doctors.
Trial design
The completed Phase 3 study (NCT06388187) enrolled 300 participants with Obesity. The trial was designed to evaluate how well different doses of CagriSema help people with excess body weight lose weight. Interventions included cagrilintide, semaglutide, and placebo.
What this means
The primary completion of this Phase 3 study indicates that data collection for the main outcomes has concluded. The next steps typically involve data analysis and the eventual release of trial results, which will provide insights into the efficacy and safety profile of CagriSema for weight loss in individuals with excess body weight.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06388187, titled 'A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight,' was updated with primary completion on April 22, 2026, on clinicaltrials.gov.